JNJ-87801493

DRUG3 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinMyelodysplastic SyndromesNeoplasmsProstatic Neoplasms, Castration-ResistantSolid Tumor, Adult

Phase 1

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

Active, not recruitingNCT06139406

Janssen Research & Development, LLCLymphoma, Non-Hodgkin

Start: 2023-12-06End: 2026-09-30Updated: 2026-08-28

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Enrolling by invitationNCT06788509

Janssen Research & Development, LLCLeukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin +4

Start: 2024-12-30End: 2028-10-30Target: 120Updated: 2026-08-28

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies

RecruitingNCT07308132

Janssen Research & Development, LLCLymphoma, Non-Hodgkin

Start: 2026-01-20End: 2029-10-31Target: 340Updated: 2026-09-10

Related Papers

Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma.

2026-02-26

JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models

Blood2024-11-053 citations